Antifungal Agents Market Overview
The antifungal agents market will reach USD 2.85 billion and a CAGR of 3.5% in the forecast period by 2027.
The antifungal medication, called antimycotic medication, is a pharmaceutical fungicide for the treatment and prevention of mycoses like ringworm, candidiasis, cryptococcal meningitis, and others. There are antifungal drugs available to combat fungal infections. Antifungal drugs are diverse. They are given orally, with topical treatment, or via IV.
Antifungal agents are used for fungal infection treatment. According to the global action fund for fungal infection, over 300 billion suffer from a serious fungal infection every year.
The increased growth of the global antifungal market is due to the rise in cases of fungal and nosocomial infections. Additionally, the surge in initiatives by public and private organizations for awareness about fungal infections will expand the antifungal drugs market. Moreover, the growth of fungal infections such as aspergillosis and candidiasis is the key factor that propels the growth of the antifungal market.
The market drivers include rising concern of fungal infections, awareness, the rise of immunity deficient populations like geriatrics, exposure to infectious agents, and environmental factors such as pollution, particulates, and agriculture residues. The growth of fungal infection due to broad-spectrum antibiotics is another cause behind the growth of the antifungal agents market.
Middle East and Africa Anti-fungal Agents Market, by Product Type, 2015 (%):
Study Objectives Middle East and Africa Anti-Fungal Agents Market:
Key Players for Middle East and Africa Anti-fungal agents Market: Some of the key players in this market are: Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others.
Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.
In May 2022
SCYNEXIS, Inc., a global biotechnology company with pioneering innovative medicines to overcome and prevent drug-resistant infections, to present data from its ongoing FURI study of ibrexafungerp during the American College of Obstetricians and Gynecologists meeting being held in San Diego on May 6-8, 2022.
In May 2022
FDA Approves Vivjoa or Chronic Yeast Infections. It is the first FDA-approved trusted Source antifungal medication to treat yeast infection.
The FDA has approved the drug based on phase three clinical trials with 875 patients. Participants in one group received Vivjoa for an initial infection and then for 50 weeks as a maintenance medication. The second group received fluconazole, a traditional treatment for yeast infections, and a placebo for 50 weeks.
Regional Analysis of Middle East and Africa Anti-fungal agents Market:
UAE is the largest market for anti-fungal agents in entire Middle East and Africa anti-fungal agents Market closely followed by Egypt. The rest of Africa market is however the fastest growing with a huge unmet medical needs and peculiar climatic conditions that support growth of fungal infections.
The report for Middle East and Africa Anti-fungal agents Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
|Market Size||USD 2.85 billion : 2027|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||by Product Type, by Therapeutic Indication, Drug Class, Route of Administration|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others.|
|Key Market Opportunities||new product developments, and research and developments globally.|
|Key Market Drivers||rising concern of fungal infections, awareness|
The MEA anti-fungal agents market is projected grow at approximately 3.5% CAGR during the assessment period (2020-2027).
The valuation of the MEA anti-fungal agents market is estimated to increase to USD 2.85 billion by the end of 2027.
Pfizer, Inc., Novartis AG, Sanofi-Aventis, Enzon Pharmaceuticals, Inc., Merck & Co., Inc., Bayer AG, GlaxoSmithKline plc, Astellas Pharma, Inc., Abbott, and Sigma-Aldrich, are some of the major players operating in the MEA anti-fungal agents market.
The UAE holds the largest share in the MEA anti-fungal agents market, followed by Egypt and the rest of Africa, respectively.
Growing awareness among populaces, rising prevalence of fungal infections, and off label use of broad spectrum antibiotics are the major tailwinds pushing the growth of the MEA anti-fungal agents market.